EP1011709A4 - Inhibition of apoptotis using prosaposin receptor agonists - Google Patents

Inhibition of apoptotis using prosaposin receptor agonists

Info

Publication number
EP1011709A4
EP1011709A4 EP98951917A EP98951917A EP1011709A4 EP 1011709 A4 EP1011709 A4 EP 1011709A4 EP 98951917 A EP98951917 A EP 98951917A EP 98951917 A EP98951917 A EP 98951917A EP 1011709 A4 EP1011709 A4 EP 1011709A4
Authority
EP
European Patent Office
Prior art keywords
apoptotis
inhibition
receptor agonists
prosaposin receptor
prosaposin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98951917A
Other languages
German (de)
French (fr)
Other versions
EP1011709A1 (en
Inventor
John S O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1011709A1 publication Critical patent/EP1011709A1/en
Publication of EP1011709A4 publication Critical patent/EP1011709A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98951917A 1997-09-09 1998-09-09 Inhibition of apoptotis using prosaposin receptor agonists Withdrawn EP1011709A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5835297P 1997-09-09 1997-09-09
US8812998P 1998-06-04 1998-06-04
US88129P 1998-06-04
PCT/US1998/019216 WO1999012559A1 (en) 1997-09-09 1998-09-09 Inhibition of apoptotis using prosaposin receptor agonists
US58352P 2008-06-03

Publications (2)

Publication Number Publication Date
EP1011709A1 EP1011709A1 (en) 2000-06-28
EP1011709A4 true EP1011709A4 (en) 2003-06-18

Family

ID=26737533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98951917A Withdrawn EP1011709A4 (en) 1997-09-09 1998-09-09 Inhibition of apoptotis using prosaposin receptor agonists

Country Status (5)

Country Link
EP (1) EP1011709A4 (en)
JP (1) JP2001515866A (en)
AU (1) AU9774698A (en)
CA (1) CA2304108A1 (en)
WO (1) WO1999012559A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
WO1999064062A1 (en) * 1998-06-08 1999-12-16 Pharmacia & Upjohn Ab New therapeutic use of pkb (proteine kinase b) enhancers
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
CA2341325A1 (en) * 1998-09-09 2000-03-16 Myelos Corporation Method of stimulating prosaposin receptor activity
JP2002528390A (en) * 1998-10-02 2002-09-03 セント エリザベス メディカル センター， インコーポレイテッド AKT composition for enhancing cell survival
US7368420B1 (en) 1998-10-02 2008-05-06 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Akt compositions for enhancing survival of cells
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
JP2001010972A (en) * 1999-06-30 2001-01-16 Masahiro Sakanaka Cytoprotective agent comprising peptide relating to prosaposin
AU2001233715A1 (en) * 2000-01-26 2001-08-07 Memorec Medical Molecular Research Cologne Stoffel Gmbh Dermo- and gastro-specific sphingolipid activator
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
DE10037759A1 (en) * 2000-08-03 2002-07-04 Gruenenthal Gmbh screening process
EP1673102A1 (en) * 2003-10-17 2006-06-28 Crucell Holland B.V. Treatment and prevention of decubitus
JP2007526022A (en) * 2003-10-24 2007-09-13 メドトロニック・インコーポレーテッド Techniques for treating neurological disorders by diminishing the production of pro-inflammatory mediators
EP3666284A1 (en) 2007-06-22 2020-06-17 Children's Medical Center, Corp. Methods and uses thereof of a fragment of saposin a
JP6727129B2 (en) 2014-03-26 2020-07-22 ザ チルドレンズ メディカル センター コーポレーション Cyclic prosaposin peptides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAMPANA W M ET AL: "Prosaptide, a peptide derived from prosaposin, induces motor endplate sprouting and prevents taxol neuropathy.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 21, no. 1-3, 1995, 25th Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 11-16, 1995, pages 554, XP009008629, ISSN: 0190-5295 *
HIRAIWA ET AL: "CELL DEATH PREVENTION, MITOGEN-ACTIVATED PROTEIN KINASE STIMULATION, AND INCREASED SULFATIDE CONCENTRATIONS IN SCHWANN CELLS AND OLIGODENDROCYTES BY PROSAPOSIN AND PROSAPTIDES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, April 1997 (1997-04-01), pages 4778 - 4781, XP002135051, ISSN: 0027-8424 *
HOZUMI I ET AL: "Amelioration of spatial learning impairment and neuronal loss in rats with stab wounds by prosaposin.", JOURNAL OF NEUROCHEMISTRY, vol. 69, no. SUPPL., 1997, Joint Sixteenth Biennial Meeting of the International Society for Neurochemistry and Twenty-eighth Annual Meeting of the American Society for Neurochemistry;Boston, Massachusetts, USA; July 20-26, 199, pages S249, XP009008631, ISSN: 0022-3042 *
OTERO DEBORAH A C ET AL: "Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model by Prosaptide(R) TX14(A).", NEUROSCIENCE LETTERS, vol. 270, no. 1, 23 July 1999 (1999-07-23), pages 29 - 32, XP002238179, ISSN: 0304-3940 *
See also references of WO9912559A1 *
TAYLOR E M ET AL: "Prosaposin and prosaptide prevent TNF-alpha-induced cell death in NS20Y and CG4 cells.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, 27th Annual Meeting of the Society for Neuroscience;New Orleans, Louisiana, USA; October 25-30, 1997, pages 2226, XP009008626, ISSN: 0190-5295 *
TSUBOI K ET AL: "Prosaposin and prosaptide can prevent programmed cell death of rat cerebellar granule neurons.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, 27th Annual Meeting of the Society for Neuroscience;New Orleans, Louisiana, USA; October 25-30, 1997, pages 1439, XP009008627, ISSN: 0190-5295 *
TSUBOI K ET AL: "PROSAPOSIN PREVENTS PROGRAMMED CELL DEATH OF RAT CEREBELLAR GRANULENEURONS IN CULTURE", DEVELOPMENTAL BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 110, no. 2, 1998, pages 249 - 255, XP000915816, ISSN: 0165-3806 *
WAGNER ROCHELLE ET AL: "Prosaptide prevents hyperalgesia and reduces peripheral TNFR1 expression following TNF-alpha nerve injection.", NEUROREPORT, vol. 9, no. 12, 24 August 1998 (1998-08-24), pages 2827 - 2831, XP009008642, ISSN: 0959-4965 *
YAN L ET AL: "A 14-mer prosaptide activates a G-protein receptor and diminishes calcium flux in synaptosomes.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, 28th Annual Meeting of the Society for Neuroscience, Part 1;Los Angeles, California, USA; November 7-12, 1998, pages 805, XP009009360, ISSN: 0190-5295 *
YAN LIZHEN ET AL: "ProsaptideTM D5 reverses hyperalgesia: Inhibition of calcium channels through a pertussis toxin-sensitive G-protein mechanism in the rat.", NEUROSCIENCE LETTERS, vol. 278, no. 1-2, 7 January 2000 (2000-01-07), pages 120 - 122, XP002238180, ISSN: 0304-3940 *

Also Published As

Publication number Publication date
JP2001515866A (en) 2001-09-25
EP1011709A1 (en) 2000-06-28
WO1999012559A1 (en) 1999-03-18
CA2304108A1 (en) 1999-03-18
AU9774698A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
IL137412A0 (en) β2-ADRENERGIC RECEPTOR AGONISTS
EG23913A (en) Estrogen agonists / antagonists
EP0979228A4 (en) Novel cannabinoid receptor agonists
PL339134A1 (en) Antagonists of il-8 receptor
IL133870A0 (en) Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
EP1011709A4 (en) Inhibition of apoptotis using prosaposin receptor agonists
PL331539A1 (en) Antagonists of il-8 receptor
ZA963535B (en) Adhesion receptor antagonists
ZA951345B (en) Adhesion receptor antagonist
PL341114A1 (en) Antagonists of thrombosin receptors
PL330195A1 (en) Antagonist of dopamine d4 receptor
IL133920A0 (en) Trail receptor
PL334774A1 (en) Antagonists of il-8 receptor
HU9702039D0 (en) Estrogen agonist/antagonists treatment of atheroscerosis
GB9617923D0 (en) Novel receptor
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
ZA963569B (en) New pharmacological use of all-receptor antagonists
PL338455A1 (en) Metho dof obtaining cyclopropyl acetylene
PL320638A1 (en) Antagonists of endothein receptors
ZA961159B (en) Adhesion receptor antagonists
GB9811216D0 (en) Plumbing line
ZA981206B (en) Use of NMDA receptor antagonist
AU2003200887A1 (en) Inhibition of Apoptosis Using Prosaposin Receptor Agonists
EP0859787A4 (en) G-protein coupled receptor hnfds78
GB9603451D0 (en) A method for inhibiting activation of the human A3 adenosine receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030506

17Q First examination report despatched

Effective date: 20031118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040330